324 related articles for article (PubMed ID: 25398834)
21. Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.
Risnik D; Colado A; Podaza E; Almejún MB; Elías EE; Bezares RF; Fernández-Grecco H; Seija N; Oppezzo P; Borge M; Gamberale R; Giordano M
Cancer Immunol Immunother; 2020 May; 69(5):813-824. PubMed ID: 32055920
[TBL] [Abstract][Full Text] [Related]
22. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
Chen CI; Bergsagel PL; Paul H; Xu W; Lau A; Dave N; Kukreti V; Wei E; Leung-Hagesteijn C; Li ZH; Brandwein J; Pantoja M; Johnston J; Gibson S; Hernandez T; Spaner D; Trudel S
J Clin Oncol; 2011 Mar; 29(9):1175-81. PubMed ID: 21189385
[TBL] [Abstract][Full Text] [Related]
23. Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.
Riches JC; Gribben JG
Curr Cancer Drug Targets; 2016; 16(8):689-700. PubMed ID: 27055579
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
Browning RL; Byrd WH; Gupta N; Jones J; Mo X; Hertlein E; Yu L; Muthusamy N; Byrd JC
Cancer Immunol Res; 2016 Aug; 4(8):698-707. PubMed ID: 27287425
[TBL] [Abstract][Full Text] [Related]
25. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.
Fecteau JF; Corral LG; Ghia EM; Gaidarova S; Futalan D; Bharati IS; Cathers B; Schwaederlé M; Cui B; Lopez-Girona A; Messmer D; Kipps TJ
Blood; 2014 Sep; 124(10):1637-44. PubMed ID: 24990888
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
29. Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.
Knudsen PB; Hanna B; Ohl S; Sellner L; Zenz T; Döhner H; Stilgenbauer S; Larsen TO; Lichter P; Seiffert M
Leukemia; 2014 Jun; 28(6):1289-98. PubMed ID: 24280868
[TBL] [Abstract][Full Text] [Related]
30. Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.
Aue G; Sun C; Liu D; Park JH; Pittaluga S; Tian X; Lee E; Soto S; Valdez J; Maric I; Stetler-Stevenson M; Yuan C; Nakamura Y; Muranski P; Wiestner A
J Immunol; 2018 Oct; 201(7):1967-1974. PubMed ID: 30104242
[TBL] [Abstract][Full Text] [Related]
31. Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation.
Zhang J; Cao D; Yu S; Chen L; Wei D; Shen C; Zhuang L; Wang Q; Xu X; Tong Y
BMC Cancer; 2018 Apr; 18(1):467. PubMed ID: 29695237
[TBL] [Abstract][Full Text] [Related]
32. Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.
Maffei R; Fiorcari S; Bulgarelli J; Martinelli S; Castelli I; Deaglio S; Debbia G; Fontana M; Coluccio V; Bonacorsi G; Zucchini P; Narni F; Torelli G; Luppi M; Marasca R
Haematologica; 2012 Jun; 97(6):952-60. PubMed ID: 22207686
[TBL] [Abstract][Full Text] [Related]
33. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.
Stamatopoulos B; Meuleman N; De Bruyn C; Mineur P; Martiat P; Bron D; Lagneaux L
Leukemia; 2009 Dec; 23(12):2281-9. PubMed ID: 19710697
[TBL] [Abstract][Full Text] [Related]
34. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
Andritsos LA; Johnson AJ; Lozanski G; Blum W; Kefauver C; Awan F; Smith LL; Lapalombella R; May SE; Raymond CA; Wang DS; Knight RD; Ruppert AS; Lehman A; Jarjoura D; Chen CS; Byrd JC
J Clin Oncol; 2008 May; 26(15):2519-25. PubMed ID: 18427150
[TBL] [Abstract][Full Text] [Related]
35. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
Ramsay AG; Clear AJ; Fatah R; Gribben JG
Blood; 2012 Aug; 120(7):1412-21. PubMed ID: 22547582
[TBL] [Abstract][Full Text] [Related]
36. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.
Chanan-Khan AA; Chitta K; Ersing N; Paulus A; Masood A; Sher T; Swaika A; Wallace PK; Mashtare TL; Wilding G; Lee K; Czuczman MS; Borrello I; Bangia N
Br J Haematol; 2011 Nov; 155(4):457-67. PubMed ID: 22010965
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide, an antiproliferative CLL drug.
Seiffert M
Blood; 2014 Sep; 124(10):1545-6. PubMed ID: 25190749
[TBL] [Abstract][Full Text] [Related]
38. Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.
Galletti G; Scielzo C; Barbaglio F; Rodriguez TV; Riba M; Lazarevic D; Cittaro D; Simonetti G; Ranghetti P; Scarfò L; Ponzoni M; Rocchi M; Corti A; Anselmo A; van Rooijen N; Klein C; Ries CH; Ghia P; De Palma M; Caligaris-Cappio F; Bertilaccio MTS
Cell Rep; 2016 Feb; 14(7):1748-1760. PubMed ID: 26876171
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells.
D'Arena G; Ruggieri V; D'Auria F; La Rocca F; Simeon V; Statuto T; Caivano A; Telesca D; Del Vecchio L; Musto P
Leuk Lymphoma; 2015; 56(8):2458-9. PubMed ID: 25547653
[No Abstract] [Full Text] [Related]
40. Antisense CD11b integrin inhibits the development of a differentiated monocyte/macrophage phenotype in human leukemia cells.
Prudovsky I; Popov K; Akimov S; Serov S; Zelenin A; Meinhardt G; Baier P; Sohn C; Hass R
Eur J Cell Biol; 2002 Jan; 81(1):36-42. PubMed ID: 11893077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
